---
schema_version: "secwatch.filing_event.v1"
accession: "0001828185-26-000004"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2026-01-06T23:59:59+00:00"
generated_at: "2026-05-16T11:33:17.417589+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Barinthus Biotherapeutics receives Nasdaq delinquency notice over bid price below $1.00 per ADR

## Summary
- On Dec 30, 2025, Nasdaq notified Barinthus that its ADS bid price was below $1.00 for 30 consecutive business days, violating Listing Rule 5450(a)(1).
- Company has 180 calendar days, until June 29, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days.
- If not compliant by deadline, a second 180-day period may be available if certain conditions are met; company evaluating options including a reverse stock split.

## SEC filing metadata
- accession: 0001828185-26-000004
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2026-01-06T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000182818526000004/0001828185-26-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000182818526000004/brns-20251230.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001828185-26-000004
- JSON: https://secwatch.observer/filing/0001828185-26-000004.json
- Plain text: https://secwatch.observer/filing/0001828185-26-000004.txt

## Source-grounded claims
- claim_id: 8d317986e42f1042334e48ebb3c30f7bdc9c653c
  claim: Barinthus Biotherapeutics plc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
  evidence_excerpt: December 30, 2025, Barinthus Biotherapeutics plc (the “Company”) received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the closing bid price of the Company’s American Depositary Shares (the “ADS”), each representing one ordinary share of the Company, was below $1.00 per share for 30 consecutive business days, and that, therefore, the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), which is the minimum bid price requirement for continued listing on the Nasdaq Global Market. The notice from Nasdaq has no immediate effect on the listing of the ADSs, and t
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828185/000182818526000004/0001828185-26-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.